Global Intra-Uterine Contraceptive Devices Market is Reaching +3.5% of CAGR by 2024

The new published report “Intra-Uterine Contraceptive Devices Market 2017: Product, Size, Share, Top Players, Drivers Analysis, End-User, Geography and Global Trends & Forecasts to 2024”, also the Global Intra-Uterine Contraceptive Devices Market is expected to reach USD 4,851.2 million by 2024 from USD 3,684.1 million in 2016, at a CAGR of 3.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

The Global Intra-Uterine Contraceptive Devices Market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Bayer AG dominated the IUCD devices market accounting for a highest market share in 2016, followed by Teva Pharmaceuticals Industries Ltd., and Mona Lisa N.V. Some of the other players in this market include DKT International, Egemen International, Melbea AG, Ocon Medical Ltd., Pregna International Limited, Medical Engineering Corporation SA and, SMB Corporation and Meril Life Sciences Pvt. Ltd., Medu Scientific Ltd, China RH Contraceptives Co., Ltd, Sanghai Jolly Medical Education Co., Ltd, Bernstein Leibhard LLP, Zheijang Daji Medical Instruments, Ltd., Nimble International, AME Line, Technico, Cepeo, Contraceptivos, Injeflex Ind And Com Ltda, Bersil, Amed among others holds 34.0% of the IUCD delivery market in 2016.

Request For Free Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-intra-uterine-contraceptive-devices-market

BAYER HEALTHCARE AG

Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a provider of healthcare, nutrition, and high-technology materials and services. The company has three business segments, namely, HealthCare, Crop Science, and Material Science. The HealthCare segment offers a wide range of products under animal health, pharmaceuticals, consumer care, and medical care. The pharmaceutical business offers a wide range of products in the therapeutic area of oncology, haematology, and ophthalmology, and offers products for women’s health and cardiology therapeutic applications

Recent Developments:

1. In October 2016, Bayer AG has successfully concluded the European registration procedure to gain EUwide marketing authorization for its new low-dose levonorgestrel-releasing intrauterine system (LNGIUS). The product is named Kyleena and will be available in the market from 2017 January.


2. In September 2016, Bayer AG has successfully received FDA approval for its new low-dose levonorgestrel releasing intrauterine system (LNG-IUS) “Kyleena” The launch of this product in October in U.S.

1. INTRODUCTION


2. RESEARCH METHODOLOGY


3. MARKET OVERVIEW


4. EXECUTIVE SUMMARY


5. PREMIUM INSIGHTS


6. GLOBAL INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET, BY PRODUCT TYPE


7. GLOBAL INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET, BY GEOGRAPHY


8. GLOBAL INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET: COMPETITIVE LANDSCAPE

9. GLOBAL INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET, COMPANY PROFILES